Literature DB >> 26837595

Implications of endogenous roles of transporters for drug discovery: hitchhiking and metabolite-likeness.

Douglas B Kell1.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 26837595     DOI： 10.1038/nrd.2015.44

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  10 in total

Review 1.  Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule?

Authors:  Paul D Dobson; Douglas B Kell
Journal:  Nat Rev Drug Discov       Date:  2008-03       Impact factor: 84.694

Review 2.  What do drug transporters really do?

Authors:  Sanjay K Nigam
Journal:  Nat Rev Drug Discov       Date:  2014-12-05       Impact factor: 84.694

Review 3.  Finding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening and knowledge of transporters: where drug discovery went wrong and how to fix it.

Authors:  Douglas B Kell
Journal:  FEBS J       Date:  2013-04-22       Impact factor: 5.542

Review 4.  A Call for Systematic Research on Solute Carriers.

Authors:  Adrián César-Razquin; Berend Snijder; Tristan Frappier-Brinton; Ruth Isserlin; Gergely Gyimesi; Xiaoyun Bai; Reinhart A Reithmeier; David Hepworth; Matthias A Hediger; Aled M Edwards; Giulio Superti-Furga
Journal:  Cell       Date:  2015-07-30       Impact factor: 41.582

5.  Natural product-likeness score revisited: an open-source, open-data implementation.

Authors:  Kalai Vanii Jayaseelan; Pablo Moreno; Andreas Truszkowski; Peter Ertl; Christoph Steinbeck
Journal:  BMC Bioinformatics       Date:  2012-05-20       Impact factor: 3.169

6.  The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity.

Authors:  Branka Radic; Cristina Mayor-Ruiz; Georg E Winter; Vincent A Blomen; Claudia Trefzer; Richard K Kandasamy; Kilian V M Huber; Manuela Gridling; Doris Chen; Thorsten Klampfl; Robert Kralovics; Stefan Kubicek; Oscar Fernandez-Capetillo; Thijn R Brummelkamp; Giulio Superti-Furga
Journal:  Nat Chem Biol       Date:  2014-07-27       Impact factor: 16.174

Review 7.  How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion.

Authors:  Douglas B Kell; Stephen G Oliver
Journal:  Front Pharmacol       Date:  2014-10-31       Impact factor: 5.810

8.  A 'rule of 0.5' for the metabolite-likeness of approved pharmaceutical drugs.

Authors:  Steve O Hagan; Neil Swainston; Julia Handl; Douglas B Kell
Journal:  Metabolomics       Date:  2014-09-19       Impact factor: 4.290

9.  The apparent permeabilities of Caco-2 cells to marketed drugs: magnitude, and independence from both biophysical properties and endogenite similarities.

Authors:  Steve O'Hagan; Douglas B Kell
Journal:  PeerJ       Date:  2015-11-17       Impact factor: 2.984

Review 10.  Fitting Transporter Activities to Cellular Drug Concentrations and Fluxes: Why the Bumblebee Can Fly.

Authors:  Pedro Mendes; Stephen G Oliver; Douglas B Kell
Journal:  Trends Pharmacol Sci       Date:  2015-11-01       Impact factor: 14.819
  10 in total
  15 in total

1.  L-5-hydroxytryptophan promotes antitumor immunity by inhibiting PD-L1 inducible expression.

Authors:  Jing Huang; Xiaobo Wang; Bing Li; Shiyu Shen; Ruina Wang; Hongru Tao; Junchi Hu; Jin Yu; Hualiang Jiang; Kaixian Chen; Cheng Luo; Yongjun Dang; Yuanyuan Zhang
Journal:  J Immunother Cancer       Date:  2022-06       Impact factor: 12.469

Review 2.  An Analysis of Mechanisms for Cellular Uptake of miRNAs to Enhance Drug Delivery and Efficacy in Cancer Chemoresistance.

Authors:  Justine M Grixti; Duncan Ayers; Philip J R Day
Journal:  Noncoding RNA       Date:  2021-04-16

3.  Exploiting AR-Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155.

Authors:  Michael D Nyquist; Alexandra Corella; John Burns; Ilsa Coleman; Shuai Gao; Robin Tharakan; Luke Riggan; Changmeng Cai; Eva Corey; Peter S Nelson; Elahe A Mostaghel
Journal:  Mol Cancer Res       Date:  2017-05       Impact factor: 6.333

4.  MetMaxStruct: A Tversky-Similarity-Based Strategy for Analysing the (Sub)Structural Similarities of Drugs and Endogenous Metabolites.

Authors:  Steve O'Hagan; Douglas B Kell
Journal:  Front Pharmacol       Date:  2016-08-22       Impact factor: 5.810

5.  Analysis of drug-endogenous human metabolite similarities in terms of their maximum common substructures.

Authors:  Steve O'Hagan; Douglas B Kell
Journal:  J Cheminform       Date:  2017-03-09       Impact factor: 5.514

6.  Drug repositioning for enzyme modulator based on human metabolite-likeness.

Authors:  Yoon Hyeok Lee; Hojae Choi; Seongyong Park; Boah Lee; Gwan-Su Yi
Journal:  BMC Bioinformatics       Date:  2017-05-31       Impact factor: 3.169

7.  Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine.

Authors:  Justine M Grixti; Steve O'Hagan; Philip J Day; Douglas B Kell
Journal:  Front Pharmacol       Date:  2017-03-27       Impact factor: 5.810

8.  HATRIC-based identification of receptors for orphan ligands.

Authors:  Nadine Sobotzki; Michael A Schafroth; Alina Rudnicka; Anika Koetemann; Florian Marty; Sandra Goetze; Yohei Yamauchi; Erick M Carreira; Bernd Wollscheid
Journal:  Nat Commun       Date:  2018-04-17       Impact factor: 14.919

9.  A substrate-based ontology for human solute carriers.

Authors:  Eva Meixner; Ulrich Goldmann; Vitaly Sedlyarov; Stefania Scorzoni; Manuele Rebsamen; Enrico Girardi; Giulio Superti-Furga
Journal:  Mol Syst Biol       Date:  2020-07       Impact factor: 11.429

Review 10.  Advances in Understanding the Mechanism of Action of the Auxin Permease AUX1.

Authors:  Gaurav Singh; Katarzyna Retzer; Stanislav Vosolsobě; Richard Napier
Journal:  Int J Mol Sci       Date:  2018-10-30       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.